D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy
NCT ID: NCT03280641
Last Updated: 2017-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1194 participants
OBSERVATIONAL
2015-08-09
2017-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
NCT03536611
The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients
NCT02646267
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
NCT03885180
D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD
NCT03261284
Monitor System for the Safety of Dabigatran Treatment
NCT02414035
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dabigatran Group
Patiets with atrial fibrillation received dabigatran (110mg, bid).
Dabigatran Etexilate 110mg
Dabigatran Etexilate 110mg, BID
Warfarin Group
Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
Warfarin Sodium
Target INR:1.6-3.0
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dabigatran Etexilate 110mg
Dabigatran Etexilate 110mg, BID
Warfarin Sodium
Target INR:1.6-3.0
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving oral anticoagulation therapy and have good compliance
Exclusion Criteria
* Thrombosis or major bleeding history within 3 months
* Refusal to Participate
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuhan Asia Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Litao ZHANG, MD
Role: PRINCIPAL_INVESTIGATOR
Wuhan Asia Heart Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
WAHH
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-P-016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.